Sisu's proprietary HI-LiTe platform (HSF1 Interacting-Ligand Technology) facilitates discovery and optimization of small molecules that bind directly to HSF1 to modulate its activity. Direct engagement with the previously "undruggable" target enables Sisu to inhibit or activate HSF1 in specific disease states.
The discovery of the first direct and selective HSF1 binding small molecule by Sisu scientific founders was published in the journal Science Translational Medicine. This highlights selective nuclear HSF1 degradation and tumor regression in Prostate Cancer models.
The paper shows that HSF1 is essential for Leukemia Stem Cell self-renewal and disease progression in AML. The discoveries are highlighted using genetic techniques and Sisu's HSF1 degrader molecules